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ABSTRACT
Objective To examine the association between pre-
diagnostic circulating vitamin D concentration, dietary
intake of vitamin D and calcium, and the risk of colorectal
cancer in European populations.
Design Nested case-control study.
Setting The study was conducted within the EPIC study, a
cohort ofmore than 520000 participants from10western
European countries.
Participants 1248 cases of incident colorectal cancer,
which developed after enrolment into the cohort, were
matched to 1248 controls
Main outcome measures Circulating vitamin D
concentration (25-hydroxy-vitamin-D, 25-(OH)D) was
measured by enzyme immunoassay. Dietary and lifestyle
data were obtained from questionnaires. Incidence rate
ratios and 95% confidence intervals for the risk of
colorectal cancer by 25-(OH)D concentration and levels of
dietary calcium and vitamin D intake were estimated from
multivariate conditional logistic regression models, with
adjustment for potential dietary and other confounders.
Results 25-(OH)D concentration showed a strong inverse
linear dose-response association with risk of colorectal
cancer (P for trend <0.001). Compared with a pre-defined
mid-level concentration of 25-(OH)D (50.0-75.0 nmol/l),
lower levelswere associatedwith higher colorectal cancer
risk (<25.0 nmol/l: incidence rate ratio 1.32 (95%
confidence interval 0.87 to 2.01); 25.0-49.9 nmol/l: 1.28
(1.05 to 1.56), and higher concentrations associated
with lower risk (75.0-99.9 nmol/l: 0.88 (0.68 to 1.13);
≥100.0 nmol/l: 0.77 (0.56 to 1.06)). In analyses by
quintile of 25-(OH)D concentration, patients in the
highest quintile had a 40% lower risk of colorectal cancer
than did those in the lowest quintile (P<0.001). Subgroup
analyses showed a strong association for colon but not
rectal cancer (P for heterogeneity=0.048). Greater dietary
intake of calcium was associated with a lower colorectal
cancer risk. Dietary vitamin D was not associated with
disease risk. Findings did not vary by sex and were not
altered by corrections for season or month of blood
donation.
Conclusions The results of this large observational study
indicate a strong inverse association between levels of
pre-diagnostic 25-(OH)D concentration and risk of
colorectal cancer in western European populations.
Further randomised trials are needed to assess whether
increases in circulating 25-(OH)D concentration can
effectively decrease the risk of colorectal cancer.
INTRODUCTION
Vitamin D can be derived from the diet but in most
populations it is mainly produced endogenously from
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sun exposure.1 The primary role of vitamin D is the
maintenance of calcium homoeostasis and bone meta-
bolism.VitaminDmight also play an important part in
cancer control by modulating cellular growth and
apoptosis and by reducing angiogenesis.2
An effect of vitamin D on cancer may be important
in the colorectum because both normal and neoplastic
colon cells can produce the active hormone from the
main circulating form25-hydroxy-vitaminD (25-(OH)
D), suggesting that it may play a direct role in control-
ling the growth of normal and neoplastic colonic
cells.3 4 However, the epidemiological evidence is not
conclusive and almost no pre-diagnostic data are avail-
able from European populations.
Most of the epidemiological data available are based
on dietary vitamin D intake and show mixed findings
from both case-control and prospective cohort
studies.5 6 These studies often do not account for endo-
genous vitamin D production from sun exposure and
are limited by measurement errors from the various
dietary assessment methods and food composition
tables used to assess its dietary intake. Such limitations
can be overcome by measuring circulating 25-(OH)D
concentration. This biomarker provides an overall
estimate of vitamin D status and integrates vitamin D
derived fromendogenousproduction and fromdietary
intake.7 However, in addition to some evidence on col-
orectal adenomas,8-12 only a few prospective studies
have measured blood 25-(OH)D concentrations, with
all but one13 reporting an inverse association with the
risk of either colorectal cancer or its anatomic sub-
sites.14-19 Nevertheless, many of these studies were
small, and all but two 1618 were based on North Amer-
ican populations.
Although vitaminDmetabolismmight bemodulated
by some dietary factors, particularly intake levels of
calcium,20 retinol21, and alcohol,2223 the potential inter-
actions have not been well studied in previous consid-
erations of the vitamin D-colorectal cancer hypothesis.
We therefore did a nested case-control study within the
European Prospective Investigation into Cancer and
Nutrition (EPIC) cohort to examine the association
between pre-diagnostic 25-(OH)D concentration and
dietary intakes of vitaminDand calciumwith colorectal
cancer risk in European populations.
METHODS
Study population and data collection
The rationale and methods of the EPIC study, includ-
ing information on dietary assessment methods, blood
collection protocols, and follow-up procedures, have
been reviewed previously.24 EPIC is a large prospec-
tive cohort study with more than 520 000 participants
enrolled from 23 centres in Denmark, France, Greece,
Germany, Italy, theNetherlands,Norway, Spain, Swe-
den, and the United Kingdom. Individuals who were
eligible for the study were selected from the general
population of a specific geographical area, town, or
province. Exceptions included the French sub-cohort,
which is based on members of the health insurance
system or state-school employees, and the Utrecht
(Netherlands) sub-cohort, which is based on women
who underwent screening for breast cancer. Between
1992 and 1998, standardised lifestyle and personal his-
tory questionnaires, anthropometric data, and blood
samples were collected from most participants at
recruitment, before disease onset or diagnosis. Diet
over the previous 12 months was assessed at recruit-
ment by validated country-specific questionnaires
designed to ensure high compliance and improved
measures of local dietary habits.24 Blood samples
were stored at the International Agency for Research
on Cancer (Lyon, France; -196°C, liquid nitrogen) for
all countries except Denmark (-150°C, nitrogen
vapour) and Sweden (-80°C freezers). Values for diet-
ary intake of total energy, vitaminD, calcium, and reti-
nol were computed using country-specific food
composition tables. Data on the intake of vitamin D
from dietary supplements were only available from a
subset of participants and are not included as a compo-
nent of the dietary vitamin D variable presented here.
Follow-up for cancer incidence and vital status
Vital status follow-up (98.4% complete) is collected by
record linkage with regional and/or national mortality
registries in all countries except Germany and Greece,
where data are collected actively. Cancer incidence is
determined through record linkage with regional can-
cer registries (Denmark, Italy, the Netherlands, Nor-
way, Spain, Sweden, and the United Kingdom;
complete up to June 2003) or via a combination of
methods, including the use of health insurance records,
contacts with cancer and pathology registries, and
active follow-up through participants and their next –
of kin (France, Germany, and Greece; complete up to
June 2002).
Nested case-control design and participant selection
Case ascertainment and selection
Colon cancers were defined as tumours in the cecum,
appendix, ascending colon, hepatic flexure, transverse
colon, splenic flexure, descending and sigmoid colon
(C18.0-C18.7 as per the 10th Revision of the Inter-
national Statistical Classification of Diseases, Injury
and Causes of Death), and overlapping or unspecified
origin tumours (C18.8 andC18.9). Rectal cancerswere
defined as tumours occurring at the rectosigmoid junc-
tion (C19) or rectum (C20). Anal canal cancers were
excluded. Colorectal cancer is the combination of the
colon and rectal cancer cases.
After exclusions (56 cases for missing matching
information, 31 cases for missing laboratory 25-(OH)
D data for the case-control set), a total of 1248 first inci-
dent colorectal cases (colon cancer=785; rectal can-
cer=463) were identified. Cases were not selected
from Norway (blood samples only recently collected;
few colorectal cancers diagnosed after blood donation)
and the Malmö centre of Sweden. The numbers of
cases for analyses of dietary vitamin D, calcium, and
retinol were 772 colon and 448 rectal because of miss-
ing nutrient intake values from Greece.
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Control selection
Controls were selected (1:1) by incidence density sam-
pling from all cohort members alive and free of cancer
at the time of diagnosis of the cases and were matched
by age (plus or minus six months at recruitment), sex,
study centre (to account for centre-specific differences
such as questionnaire design and blood collection pro-
cedures), time of the day at blood collection, and fast-
ing status at the time of blood collection (less than three
hours, three to six hours, and more than six hours).
Women were further matched by menopausal status
(pre-menopausal, post-menopausal, peri-menopau-
sal/unknown), phase of menstrual cycle at time of
blood collection, and usage of hormone replacement
therapy at time of blood collection (yes/no). The addi-
tional matching criteria for women were needed for
other studies that were being done using the same
matched case-control sets. The numbers of case-con-
trol matched sets from each country are shown in
table 1.
Laboratory assays
The feasibility and reliability of measuring 25-(OH)D
in EPIC samples has been previously established.25
Vitamin D status was quantitatively determined by
measuring 25-(OH)D in 25 μl of serum (heparin
plasma for Swedish samples) using a commercially
available enzyme immunoassay kit (OCTEIA 25-(OH
)D Kit, Immuno Diagnostic Systems, Boldon, UK) at
the Laboratory for Health Protection Research,
National Institute for Public Health and the Environ-
ment, the Netherlands. The kit is specific for 100% of
vitamin D3 origin and 75% of vitamin D2 origin. For
technical reasons, some case-control sets were not
measured in the same analytical batch. However,
batch-to-batch differences are considered to be
minor: the coefficient of variation (inter-assay) as deter-
mined with two kit control samples was minimal (5.9%
at the level of 20.3 nmol/L and 5.4% at the level of 77.4
nmol/l), no significant between-day drift, time shifts, or
other trends were observed and the percentage of var-
iance attributable to batch-to-batch differences was
4.5%. For all analyses, laboratory technicians were
blinded to the case-control status of the samples.
Statistical analysis
Differences between cases and controls in mean diet-
ary variables, circulating 25-(OH)D levels andbaseline
covariates were tested by paired t-tests of the values in
each case-control set for colon and rectum anatomical
sub-sites separately. For categorical variables (smoking
status, physical activity, education level), case-control
differences were assessed by conditional logistic
regression.
Conditional logistic regression, stratifiedby the case-
control set, was used to estimate the risk and 95% con-
fidence intervals of colorectal cancers and cancers of
the colon and rectum in relation to levels of intake of
dietary variables and circulating 25-(OH)D concentra-
tions (SAS statistical software, version 9, SAS Institute,
Cary, NC). In a nested case-control study where con-
trols are selected using incidence density sampling, this
procedure estimates the incidence rate ratio which,
given the rarity of the disease, is roughly equal to the
odds ratio.26 For dietary vitamin D and calcium, quin-
tile cut-points were based on the variable distributions
in all the controls combined. Circulating 25-(OH)D
concentration was divided into five categories with
predefined cut-points on the basis of proposed levels
of vitamin D deficiency/insufficiency:27-30 category 1:
<25.0 nmol/l, category 2: ≥25.0 to <50.0 nmol/l, cate-
gory 3 (referent): ≥50.0 to <75.0 nmol/l, category 4:
≥75.0 to 100.0 nmol/l, category 5: ≥100.0 nmol/l. A
level of between ≥50.0 and <75.0 nmol/l was assumed
as a central, mid-range reference category in order to
provide stability in the statistical analyses and for a
clearer ascertainment of the cancer risk consequences
of both lower and higher 25-(OH)D concentrations.As
an additional analysis, circulating 25-(OH)D concen-
tration was also divided by quintiles based on the dis-
tribution in the control members, with the lowest
category chosen as the referent. Quintile cut-points
are described in web table 1.
For all variables of interest, risk estimates were com-
puted as both univariate analyses based on the match-
ing factors, and multivariate analyses, with additional
adjustments for potential confounders including body
mass index (kg/m2), physical activity (combined
recreational and household activity; expressed as sex-
specific categories ofmetabolic equivalents), duration/
status/intensity of smoking (table 1), education level
(an indicator variable for socioeconomic status), total
energy intake (in quartiles), total intake of fruits (quar-
tiles), total intake of vegetables (quartiles), total intake
of red and processed meats (quartiles), and total alco-
hol intake (categorical cut-points for men: non-consu-
mers, 1 to 10, 11 to 20, 21 to 40, >40 g/day; cut-points
for women: non-consumers, 1 to 5, 6 to 15, 16 to 25,
>25 g/day). Models similar to the above were also run
with variables included in the model as log trans-
formed continuous variables with the incidence rate
ratio estimated for the risk related to a 10% increase
in the value of the variable. Potential effects of dietary
fibre intake, as well as consumption of dairy products
and fish (rich dietary sources of vitaminD) were exam-
ined, but they did not provide appreciable changes in
risk estimates and were not included in the final mod-
els. For all models, tests for linear trend were per-
formed using a score variable with values from 1 to 5,
consistent with the category/quintile grouping.
To assess any effects of the season or month of blood
collection, twodifferent approacheswereused.As a first
approach, incident rate ratios and95%confidence inter-
vals were calculated as described above but with an
additional adjustment for season of blood collection
(categorical variable: winter, spring, summer, autumn).
In a second approach, circulating 25-(OH)D concentra-
tions were standardised and the standardised values
were then used in conditional regression models as
described above. The results were then compared with
those of the non-standardised 25-(OH)D. Circulating
RESEARCH
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25-(OH)D concentrations were standardised using two
different methods: (a) by the month of blood collection
calculated by adding the overall mean of the circulating
25-(OH)D for all subjects to the residuals derived froma
simple regression model fitted to circulating 25-(OH)D
concentration by month of blood collection and (b) by
the method of Munger et al.31
All analysis models were run separately for colorec-
tal cancer and by anatomical sub-site: colon, left colon,
right colon, and rectum using the same categorical cut-
points as for colorectal cancer.
Since a primary function of vitaminD ismaintenance
of calcium homoeostasis, a potential interaction of the
effect of circulating 25-(OH)D concentration with the
level of dietary calcium intake on colorectal cancer
risk was explored by including a single degree of free-
dom interaction term formed by the product of the
25-(OH)D category value (cut-points: <50.0 nmol/l,
Table 1 | Description of cases and matched controls, by anatomical site
Colon Rectum
Cases* Matched controls
P value
difference† Cases* Matched controls
P value
difference†
Men, n 369 369 — 251 251 —
Women, n 416 416 — 212 212 —
Total 785 785 463 463
Mean age, years (SD), minimum-maximum value:
At recruitment 58.5(7.2),30.1to76.9 58.6(7.2),30.3to76.6 0.65 58.0(6.8),38.1to75.0 58.0(6.9),38.4to75.3 0.33
At blood collection 58.7 (7.3) 30.1 to 76.9 58.7 (7.3) 30.3 to 76.6 0.57 58.1 (6.9(38.1to75.0) 58.0 (6.9 38.4 to 75.3 0.21
Mean years of follow up (SD), maximum value 3.8 (2.2), 11.5 — — 3.9 (2.2), 10.3 — —
Mean BMI (SD), minimum-maximum value 26.8(4.4),17.6to52.5 26.3(3.9),17.2to49.3 0.01 26.5(4.1),15.7to41.1 26.4(3.9),17.6to44.5 0.52
Smoking status/duration/intensity, n (%): 0.52 0.63
Never smokers 330 (42.0) 356 (45.4) 179 (38.7) 179 (38.7)
Ex-smokers, duration of smoking <10 years 44 (5.6) 37 (4.7) 18 (3.9) 21 (4.5)
Ex-smokers, duration of smoking ≥10 years 200 (25.5) 203 (25.9) 127 (27.4) 115 (24.8)
Ex-smokers, missing duration of smoking 19 (2.4) 15 (1.9) 5 (1.1) 9 (1.9)
Smokers, <15 cigarettes a day 66 (8.4) 71 (9.0) 55 (11.9) 49 (10.6)
Smokers, ≥15 to <25 cigarettes a day 66 (8.4) 57 (7.3) 36 (7.8) 51 (11.0)
Smokers, ≥25 cigarettes a day 15 (1.9) 16 (2.0) 14 (3.0) 13 (2.8)
Missing smoking status 45 (5.7) 30 (3.8) 29 (6.3) 26 (5.6)
Physical activity, n (%): 0.27 0.24
Inactive 170 (21.7) 139 (17.7) 80 (17.3) 86 (18.6)
Moderately inactive 167 (21.3) 186 (23.7) 112 (24.2) 93 (20.1)
Moderately active 198 (25.4) 198 (25.2) 100 (21.6) 107 (23.1)
Active 204 (26.0) 214 (27.3) 145 (31.3) 144 (31.1)
Missing/unspecified 46 (5.9) 48 (6.1) 26 (5.6) 33 (7.1)
Education level, n (%): 0.55 0.40
None/primary 292 (27.2) 310 (39.5) 160 (34.6) 176 (38.0)
Technical/professional 186 (23.7) 185 (23.6) 127 (27.6) 128 (27.6)
Secondary 150 (19.1) 131 (16.7) 68 (14.7) 64 (13.8)
University or higher 130 (16.6) 137 (17.5) 91 (20.0) 86 (18.6)
Missing/unspecified 27 (3.4) 22 (2.8) 16 (3.5) 9 (1.9)
Dietary variables (g/day):
Total energy (MJ/day) 9.0 (3.1) 8.9 (2.7) 0.31 9.2 (2.9) 9.1 (2.6) 0.20
Total vegetables 183.7 (122.2) 190.3 (123.3) 0.20 184.2 (162.9) 182.9 (123.9) 0.87
Total fruits 233.2 (192.1) 241.2 (188.5) 0.35 218.9 (168.7) 222.4 (168.6) 0.71
Meats and meat products 112.6 (77.9) 110.2 (58.2) 0.48 123.2 (65.6) 116.8 (63.9) 0.08
Dairy and dairy products 335.0 (251.7) 350.7 (248.2) 0.20 339.3 (276.1) 374.3 (271.5) 0.05
Alcohol 16.1 (22.4) 14.7 (19.2) 0.11 20.4 (25.1) 16.8 (21.6) 0.01
Vitamin D (μg/day) 4.1 (2.6) 4.0 (2.5) 0.83 4.2 (2.7) 4.3 (2.7) 0.43
Calcium (mg/day) 985.8 (429.2) 1000.9 (406.4) 0.46 981.6 (418.0) 1038.6 (439.6) 0.05
Retinol (μg/day) 940.1 (938.0) 918.5 (890.1) 0.61 1011.9 (840.2) 999.2 (966.5) 0.83
Circulating 25-(OH)D geometric mean (5th-95th percentile):
Vitamin D (nmol/l) 51.7 (24.1-104.4) 57.2 (28.0-114.8) <0.01 54.9 (26.3-111.0) 55.4 (24.7-116.5) 0.75
Data are mean (SD) unless otherwise indicated.
*Indicates number of cases and matched controls for circulating 25-(OH)D analyses. The distribution of cases (colon/rectum) by country was: Denmark=186/167, France=28/8, Greece=12/
14, Germany=93/55, Italy=104/42, Netherlands=93/48, Spain=78/41, UK=150/64, and Sweden=41/24.
†P values for differences in means between cases and controls determined by paired t-tests, except for the categorical variables smoking status, physical activity, and education level, where
P values were determined by conditional logistic regression.
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≥50.0 to <75.0 nmol/l, ≥75.0 nmol/l) and the dietary
calcium tertile. The statistical significance of a linear
interaction was assessed using the likelihood ratio test.
Similar models were used to test for interaction of 25-
(OH)D with amount of alcohol consumption and diet-
ary retinol intake.
For all themain variables, heterogeneity of effects by
sex and anatomical subsite were assessed by χ2 statis-
tics. To assess the potential for reverse causality (lower
25-(OH)D level due to the presence of disease at enrol-
ment) and to assess the effect of follow-up time in
greater detail, analyses were also performed excluding
cases diagnosed with less than two years of follow-up.
All statistical tests were two tailed.
RESULTS
Description of study population
Mean age of participants at recruitment was similar in
both the colon (cases: 59.6 (SD 7.2); controls: 58.6 (SD
7.2)) and rectum (cases: 58.0 (SD 6.8); controls: 58.0
(SD 6.9) anatomical sub-sites (table 1). The average
time between blood collection and diagnosis was 3.
8 years for colon cancer cases and 3.9 years for rectal
cancer cases.
Circulating 25-(OH)D level
Compared with a level of ≥50.0 to <75.0 nmol/l,
higher circulating 25-(OH)D level (categories 4 and
5) was associated with a reduced risk, and lower circu-
lating 25-(OH)D concentration (categories 2 and 1)
was associated with an increased risk of colon cancer
(table 2). A linear trend was evident for colorectal can-
cer (P for trend <0.001) and colon cancer (P for trend
<0.001) but not rectal cancer (P for trend=0.320). In the
multivariate adjusted continuous model, the cancer
risks (incidence rate ratio (95% confidence interval))
associated with 10% higher level of circulating
25-(OH)D were: colorectal 0.97 (0.95 to 0.99); colon
0.95 (0.93 to 0.98); rectum 1.00 (0.97 to 1.03).
Additional analyses of risk estimates using a 25-
(OH)D concentration based on quintiles with the low-
est category as the referent are shown in web table 1.
Higher circulating 25-(OH)D concentration was asso-
ciated with lower colorectal risk in a dose-response
manner (multivariate incidence rate ratio for the lowest
versus highest quintile 0.60 (95% confidence interval
0.46 to 0.80); P for trend<0.001). The association was
stronger for the colon (0.47 (0.33 to 0.68)) than the rec-
tum (0.89 (0.56 to 1.43); web table 1).
Country-specific incidence rate ratios and 95% con-
fidence intervals indicating the colorectal cancer risk
for a 10% increase in circulating 25-(OH)D concentra-
tion were: Denmark 0.98 (0.96 to 1.01); France 0.88
(0.79 to 0.98); Germany 0.91 (0.86 to 0.97); Greece
1.00 (0.88 to 1.15); Italy 0.98 (0.94 to 1.04); theNether-
lands 1.02 (0.98 to 1.09); Spain 0.96 (0.89 to 1.03); Swe-
den 0.93 (0.83 to 1.04); and the United Kingdom 0.93
(0.88 to 0.97).
Adjustments for the seasonofblood collectiondidnot
alter any of the findings (results not shown). Differences
were apparent in circulating 25-(OH)D concentration
by month of blood collection with cases exhibiting
lower mean circulating 25-(OH)D concentration than
controls in each month (web figure 1). Assessment of
colorectal cancer risk using circulating 25-(OH)D con-
centration standardised by month of blood collection
showed a similar pattern of results (web table 2; results
in quintiles shown in web table 3) compared withmod-
els using non-standardised 25-(OH)D (table 2, web
table 1). Results for standardisation by the method of
Munger et al 31 (data not shown) were not different from
those presented in web tables 2 and 3.
Table 2 | Circulating 25-(OH)D concentration and the risk of cancers of the colorectum, colon, and rectum
Type of cancer
Pre-defined category cut-points (nmol/l)
P for trend1 (<25.0) 2 (≥25.0 to <50.0)
3 (≥50.0 to <75.0)
(reference) 4 (≥75.0 to <100.0) 5 (≥100.0)
Colorectum
Mean (SD), median (nmol/l) 19.6 (5.0), 21.4 38.7 (6.7), 39.3 61.2 (7.3), 60.0 85.1 (6.8), 84.5 125.7 (37.6), 116.1
No of cases/controls 64/52 473/400 448/461 173/209 90/126
Matching factors* 1.32 (0.89 to 1.97) 1.25 (1.03 to 1.52) 1.00 0.86 (0.68 to 1.10) 0.72 (0.53 to 0.97) <0.001
Multivariate adjusted† 1.32 (0.87 to 2.01) 1.28 (1.05 to 1.56) 1.00 0.88 (0.68 to 1.13) 0.77 (0.56 to 1.06) <0.001
Colon
Mean (SD), median (nmol/l) 19.8 (3.5), 20.4 38.9 (6.7), 39.3 60.9 (7.3), 59.9 85.5 (7.0), 85.0 123.5 (29.6), 116.3
No of cases/controls 45/27 300/249 286/295 104/138 50/76
Matching factors* 1.84 (1.10 to 3.08) 1.31 (1.03 to 1.67) 1.00 0.81 (0.60 to 1.09) 0.66 (0.44 to 0.99) <0.001
Multivariate adjusted† 1.90 (1.10 to 3.29) 1.36 (1.05 to 1.76) 1.00 0.86 (0.62 to 1.17) 0.71 (0.46 to 1.08) <0.001
Rectum
Mean (SD), median (nmol/l) 19.4 (6.3), 22.4 38.4 (6.7), 39.2 61.5 (7.3), 60.9 84.2 (6.2), 83.1 128.9 (47.5), 115.4
Matching factors* 0.76 (0.39 to 1.47) 1.19 (0.87 to 1.62) 1.00 0.99 (0.66 to 1.49) 0.80 (0.50 to 1.29) 0.288
Multivariate adjusted† 0.77 (0.37 to 1.59) 1.17 (0.84 to 1.65) 1.00 0.93 (0.60 to 1.45) 0.82 (0.48 to 1.40) 0.320
Data are incidence rate ratio (95% CI) unless indicated.
*Model based on matching factors only.
†Model based on matching factors plus further adjustments for smoking status/duration/intensity, body mass index, total physical activity, education level, total dietary energy
consumption, and intake of total fruits, vegetables, meat or meat products, and alcohol. Values for mean and median are based on control participants only.
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Dietary vitamin D
Dietary vitamin D intake did not show an association
with colorectal cancer risk (table 3). P values for linear
trend tests were: colorectal 0.187; colon 0.496; rectum
0.145. The risk associated with a 10% increase in diet-
ary vitamin D intake was (multivariate adjusted inci-
dence rate ratio, 95% confidence interval): colorectal
1.00 (0.98 to 1.01); colon 1.01 (0.99 to 1.03); rectum
0.98 (0.95 to 1.01).
Dietary calcium
Higher intake of dietary calcium showed some evi-
dence of associationwith a reduced cancer risk associa-
tion, particularly in the rectal anatomical sub-site
(table 3). P values for linear trend tests were: colorec-
tal=0.013, colon=0.152, rectum=0.026. The risk asso-
ciated with a 10% increase in dietary calcium intake
was (multivariate adjusted incidence rate ratio, 95%
confidence interval): colorectal 0.97 (0.94 to 0.99);
colon 0.98 (0.94 to 1.00); rectum 0.94 (0.90 to 0.99).
Interactions with dietary factors
The dose-response analysis of the interaction between
circulating 25-(OH)D concentration and dietary
calcium intake (P=0.154) showed that the inverse asso-
ciation between colorectal cancer risk and circulating
25-(OH)D concentration was apparent across levels of
dietary calcium. The lowest level of both variables was
associated with an increased colorectal cancer risk
(incidence rate ratio 1.33 (95% confidence interval
1.16 to 1.55); table 4). No interaction on colorectal
cancer risk was observed between circulating
25-(OH)D concentration and the level of alcohol con-
sumption (P for interaction=0.283; table 5). However,
the highest colorectal cancer riskwas seen in thosewith
the lowest circulating levels of 25-(OH)D and the
Table 3 | Dietary intakes of vitamin D and calcium and the risk of cancers of the colorectum, colon, and rectum
Quintiles of dietary intake
P for trend1 (reference) 2 3 4 5
Vitamin D intake (μg/day) <2.1 ≥2.1 to < 3.1 ≥3.1 to < 4.2 ≥4.2 to < 5.8 ≥5.8
Colorectum:
Mean (SD), median (μg/day) 1.5 (0.5), 1.6 2.5 (0.3), 2.7 3.6 (0.3), 3.6 4.9 (0.9), 4.9 8.2 (2.7), 7.3
No of cases/controls 251/243 255/245 249/244 235/246 230/244
Matching factors* 1.00 1.00 (0.78 to 1.28) 0.97 (0.74 to 1.26) 0.90 (0.68 to 1.19) 0.88 (0.66 to 1.17) 0.277
Multivariate adjusted† 1.00 1.03 (0.79 to 1.34) 0.96 (0.72 to 1.28) 0.88 (0.65 to 1.20) 0.84 (0.60 to 1.17) 0.187
Colon:
Mean (SD), median (μg/day) 1.5 (0.5), 1.6 2.7 (0.3), 2.7 3.6 (0.3), 3.6 4.9 (0.5), 4.9 8.0 (2.7), 7.3
No of cases/controls 165/163 169/154 155/149 135/160 148/147
Matching factors* 1.00 1.07 (0.78 to 1.46) 1.00 (0.72 to 1.40) 0.82 (0.58 to 1.15) 0.96 (0.67 to 1.38) 0.365
Multivariate adjusted† 1.00 1.11 (0.80 to 1.55) 1.05 (0.73 to 1.50) 0.83 (0.56 to 1.22) 1.00 (0.66 to 1.53) 0.514
Rectum:
Mean (SD), median (μg/day) 1.5 (0.4), 1.6 2.7 (0.3), 2.7 3.6 (0.3), 3.6 4.9 (0.5), 4.9 8.3 (2.8), 7.4
No of cases/controls 86/80 86/91 94/95 100/86 82/97
Matching factors* 1.00 0.87 (0.57 to 1.34) 0.93 (0.60 to 1.45) 1.09 (0.68 to 1.76) 0.78 (0.49 to 1.25) 0.546
Multivariate adjusted† 1.00 0.85 (0.52 to 1.36) 0.79 (0.48 to 1.30) 0.85 (0.49 to 1.48) 0.61 (0.34 to 1.09) 0.142
Quintiles of dietary calcium intake (mg/day) <667.2 ≥667.2 to <854.7 ≥854.7 to <1047.6 ≥1047.6 to <1299.4 ≥1299.4
Colorectum:
Mean (SD), median (mg/day) 523.9 (104.9), 544.6 766.4 (53.5), 769.7 949.2 (57.7), 947.7 1163.6 (70.3), 1163.1 1667.5 (358.0), 1574.4
No of cases/controls 269/243 258/247 258/243 213/245 222/244
Matching factors* 1.00 0.93 (0.72 to 1.20) 0.94 (0.73 to 1.22) 0.77 (0.59 to 1.00) 0.81 (0.62 to 1.05) 0.042
Multivariate Adjusted† 1.00 0.88 (0.67 to 1.15) 0.90 (0.67 to 1.20) 0.72 (0.52 to 0.96) 0.69 (0.50 to 0.96) 0.016
Colon:
Mean (SD), median (mg/day) 517.0 (107.1), 538.1 766.0 (52.8), 769.0 948.7 (57.0), 949.6 1161.1 (69.9), 1161.4 1677.1 (345.8), 1590.9
No of cases/controls 164/150 167/168 167/163 139/145 135/147
Matching factors* 1.00 0.90 (0.66 to 1.23) 0.93 (0.68 to 1.27) 0.87 (0.62 to 1.22) 0.83 (0.60 to 1.16) 0.287
Multivariate adjusted† 1.00 0.86 (0.61 to 1.21) 0.88 (0.62 to 1.27) 0.80 (0.54 to 1.18) 0.72 (0.47 to 1.10) 0.176
Rectum:
Mean (SD), median (mg/day) 534.7 (100.5), 565.5 767.2 (55.0), 770.9 950.1 (59.1), 947.5 1167.8 (71.1), 1166.8 1652.9 (376.5), 1536.4
No of cases/controls 105/93 91/79 91/80 74/100 87/97
Matching factors* 1.00 1.01 (0.66 to 1.55) 0.99 (0.63 to 1.55) 0.62 (0.40 to 0.97) 0.78 (0.51 to 1.20) 0.054
Multivariate adjusted† 1.00 0.88 (0.55 to 1.42) 0.91 (0.54 to 1.42) 0.52 (0.30 to 0.90) 0.63 (0.36 to 1.11) 0.025
Data are incidence rate ratio (95% confidence interval) unless stated otherwise.
*Model based on matching factors only.
†Model based on matching factors plus further adjustments for smoking status/duration/intensity, body mass index, total physical activity, education level, total dietary energy
consumption, and intake of total fruits, vegetables, meats/meat products and alcohol. For dietary vitamin D and calcium, the number of total colorectal cancer case-control sets is 1220 due
to missing dietary data from Greece. Values for mean and median are based on control participants only.
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highest level of alcohol consumption (incidence rate
ratio 1.46, 95% confidence interval 1.16 to 1.83). The
dose-response analysis of the interaction between cir-
culating 25-(OH)D concentration and level of dietary
retinol intake (P for interaction=0.030) indicates that
the inverse colorectal cancer risk association of higher
25-(OH)D was stronger at lower intakes of retinol
(table 5).
The cancer risk associations did not differ by sex (P
for heterogeneity: 25-(OH)D=0.782, dietary vitamin
D=0.600, dietary calcium=0.500). For circulating 25-
(OH)D, the cancer risk association showed evidence
of heterogeneity between the colon and rectal anatomi-
cal sub-sites (P for heterogeneity=0.048), but this was
not the case for dietary vitamin D (P for heterogeneity
=0.400) or dietary calcium (P for heterogene-
ity=0.300). Comparison of findings for the proximal
and distal anatomical sub-sites within the colon sug-
gested some heterogeneity for dietary calcium (P for
heterogeneity=0.010), but not for the other variables
(P for heterogeneity: 25-(OH)D=0.500, dietary vita-
min D=0.600). The exclusion of cases with less than
two years of follow-up did not change any of the results
(data not shown).
DISCUSSION
The results of this study, which is the largest to date and
one of the first based on European populations, show
that, comparedwith amid-range concentration of 50 to
75.0 nmol/l, circulating 25-(OH)D levels lower than
50.0 nmol/l are associated with an increased risk of
colorectal cancer. Although levels higher than 75.0
nmol/L were associated with a reduced colorectal can-
cer risk, the association was not significant compared
with themid-range concentration.Analyses byquintile
of 25-(OH)D concentration, showed a dose-response
decrease in colorectal cancer risk with increasing 25-
(OH)D concentration. Participants in the highest quin-
tile had a significant 40% lower risk of colorectal cancer
than did those in the lowest quintile. Additionally,
higher consumption of dietary calcium, but not dietary
vitamin D, was found to be associated with a reduced
risk of colorectal cancer.
Since the first suggestion that vitamin D may have a
role in colorectal cancer risk,32 the association has been
evaluated pre-diagnostically by only a few small
studies.13-19 Most of these studies have shown inverse
associations with colorectal cancer risk but the results
have been based mainly on North American popula-
tions with different dietary and lifestyle habits than
their western European counterparts. The strong
inverse associations of the present study suggest that
further research efforts should concentrate less on
observational findings and more on clinically relevant
studies to determine whether vitamin D has a causal
role in colorectal cancer prevention or whether it is a
marker of other events.
An important consideration for circulating 25-(OH)
D levels is what concentration should be deemed suffi-
cient for colorectal cancer protection. Results of a
recent review and meta-analysis, which included
around half as many cases as in our study suggest that
a blood 25-(OH)D level of about 80.0 nmol/l results in
a colorectal cancer risk reduction of roughly 50%.33
This level of risk reduction is in line with that observed
in our study when comparing the highest to the lowest
quintiles of 25-(OH)D. However, there is debate over
the definition of a sufficient level of circulating 25-
(OH)D and suggestions range from about 50 nmol/l30
to higher.27-29 In the present study, although cancer
risks for 25-(OH)D levels above 75 nmol/l were
lower than those in the 50-75 nmol/l mid-range refer-
ence, the differences were not statistically significant.
This finding suggests that raising very low levels of 25-
(OH)D to themid-rangemay protect against colorectal
cancer, and that levels above 75 nmol/l might not sig-
nificantly reduce the cancer risks any further, but this
needs to be proven in a clinical trial. In light of accu-
mulating evidence for a possible beneficial role of
increased circulating vitamin D levels in reducing the
risk of a range of different diseases34-37 as well as cancer
specific38 and total mortality,39 there is growing advo-
cacy for vitamin D supplementation and the mainte-
nance of higher circulating levels. However, there has
been little study into the long termhealth effects of very
high circulating 25-(OH)D concentrations potentially
obtainable from supplementation regimens or wide-
spread fortification of food products. Our findings sug-
gest that the potential cancer risk benefits of higher
vitamin D levels should be balanced with caution for
the toxic potential. In fact, any public health advocacy
of higher circulating 25-(OH)D concentrations should
bebasedon clear and conclusive evidence fromdouble
blind randomised trials, as for any drug.
We know of only one previously published clinical
trial with a primary objective of assessing the effect of
vitamin D and calcium supplementation on incidence
of colorectal cancer.40 It was conducted within the
Women’s Health Initiative and showed no effect of
supplementation (1000 mg/day of calcium and 400
IU/day of vitamin D) on colorectal cancer incidence.
Critiques of this large trial include a low level of vita-
min D supplementation, a short duration of follow-up,
low compliance, potentially sufficient levels of vitamin
D and calcium intake at baseline, and lack of informa-
tion on actual changes in circulating 25-(OH)D due to
supplementation.41 Two other trials have also pub-
lished data on supplementation of these nutrients and
the incidence of all cancers, but in both studies the
Table 4 | Incidence rate ratios for risk of colorectal cancer by increasing levels of circulating
25-(OH)D and dietary calcium
Tertiles of dietary calcium
intake level (mg/day)
Categories of serum 25-(OH)D (nmol/l)
1 (<50.0) 2(≥50.0 to <75.0) 3(≥75.0)
1 (<797.5) 1.33 (1.14 to 1.54) 1.11 (1.01 to 1.22) 0.85 (0.69 to 1.02)
2 (≥797.5 to <1113.5) 1.17 (1.07 to 1.27) 1.00 0.80 (0.69 to 0.90)
3 (≥1113.5) 0.95 (0.80 to 1.13) 0.85 (0.73 to 0.98) 0.72 (0.57 to 0.91)
Data are incidence rate ratio (95% confidence interval) derived from the multivariate adjusted models described
in the text based on a dose-response analysis with predefined categories of circulating 25-(OH)D and tertiles of
dietary calcium intake. P value for statistical interaction of circulating 25-(OH)D with dietary calcium=0.154. For
this analysis, the total number of colorectal cancer case-control sets is 1220 due to missing nutrient data from
Greece.
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assessment of cancer outcomes was a secondary
objective.42 43 Their findings were conflicting, showing
either no reduction in incidence of colorectal or all
cancers42 or a significant reduction in incidence of all
cancers, albeit with a very small number of events (n=
50).43 Whether alteration of circulating vitamin D con-
centration can change the risk for colorectal cancer
remains to be determined. In order to establish appro-
priate public health and safety guidelines, future efforts
should concentrate on the conduct of new clinical trials
of vitamin D supplementation to assess whether
increases in circulating concentration can effectively
change colorectal cancer risk.
One of the key functions of vitamin D is the main-
tenance of calcium homoeostasis. Given that there is
some epidemiological evidence for a possible inverse
association between higher calcium intake and the risk
of colorectal cancer,44-47 a biological interaction of cir-
culating 25-(OH)D levels and dietary calcium intake
may exist. However, to date the relation between diet-
ary calcium and blood 25-(OH)D concentration has
been primarily considered in studies of colorectal ade-
nomas, showing either that both nutrients act together
to reduce the risk of adenoma848 or that the inverse
association with higher 25-(OH)D concentration is
apparent only in those with lower calcium intakes.11
In the present study, a significant statistical interaction
was not observed between circulating 25-(OH)D con-
centration and dietary calcium intake. Although this
finding may not discount a potential biological inter-
action, it does suggest that some of themodes of action
of these two factors in the gastrointestinal tract might
be unconnected. For example, the main proposed col-
orectal cancer protective mechanisms of calcium
action (binding bile acids and fatty acids)46 could per-
tain largely to its concentration in the colorectal milieu
rather than to a direct vitamin D-mediated effect.
Advantages and limitations
In addition to its large size and scope, anotherkeyadvan-
tage of our study is that it is based on geographically
diverse European populations, thus encompassing
many different lifestyle patterns (including sun expo-
sure) and wide dietary heterogeneity. Further advan-
tages are its prospective design (participants recruited
before disease onset) and pre-diagnostic measurement
of circulating 25-(OH)D concentration to collectively
account fordietary consumption (limiteddietary sources
include fatty fish, egg yolk, fortified dairy products),
intake of supplements, and endogenous production.
The use of this biomarker compensates for our lack of
data on total sun exposure, sun tanning habits, and vita-
min D supplement intake.
Although the study was larger than other prospec-
tive studies on the same topic, it may still be limited
for consideration of 25-(OH)D-diet interactions. How-
ever, a more important limitation may be the fairly
short follow-up time. Cases identified within a short
period after the start of the study might have had
some symptoms, leading to dietary or lifestyle changes
and hence possible alterations in the circulating 25-
(OH)D concentration or dietary calcium level (reverse
causality bias). However, exclusion of cases with less
than two years of follow-up did not alter any of the
findings, suggesting that cases diagnosed close to
study entry might not be different from those diag-
nosed later. But, in view of the long term nature of col-
orectal cancer development and the short follow-up
time, some caution is still necessary in the inter-
pretation of these results. An additional potential lim-
itation applicable to all observational studies is the
possibility for residual or uncontrolled confounding.
The dietary and lifestyle data of the EPIC study have
been well measured and validated. Nevertheless, the
possibility of residual confounding cannot ever be
wholly discounted. Uncontrolled confounding is unli-
kely because the multivariate adjusted model pre-
sented here addressed a large number of potentially
important confounding variables including anthropo-
metry, smoking, physical activity, socioeconomic sta-
tus, total energy intake, and consumption of fruits,
vegetables, red and processed meats, and alcohol. A
potential confounding variable not controlled for
here is colorectal cancer screening, which is still
uncommon in Europe49 and thus not likely to have
had an effect on our findings.
Conclusions
This comprehensive study, based on western European
populations in the prospective EPIC cohort, has shown
that pre-diagnostic concentrations of circulating 25-
(OH)Dbelow50nmol/l are associatedwithan increased
risk of colon cancer, whereas concentrations above 75.0
nmol/l are associated with a non-significant reduced
risk. Comparison of lowest to highest quintiles of 25-
(OH)D concentration showed that participants in the
highest quintile had a significant 40% lower colorectal
cancer risk. However, before any public health recom-
mendations can be made for vitamin D supplementa-
tion, new randomised trials are needed to test the
hypothesis that increases in circulating 25-(OH)D con-
centration are effective in reducing colorectal cancer risk
without inducing serious adverse events.
Table 5 | Incidence rate ratios for risk of colorectal cancer by increasing levels of circulating
25-(OH)D and alcohol and dietary retinol
Categories of circulating 25-(OH)D (nmol/l)
1 (<50.0) 2 (50.0 to <75.0) 3 (≥75.0)
Sex specific categories of dietary alcohol intake level (g/day)
1 (men <1.0, women <1.0) 1.13 (1.03 to 1.26) 1.00 0.82 (0.70 to 0.96)
2 (men 1.0 to <25.0, women 1.0
to <15.0)
1.19 (1.07 to 1.32) 1.04 (1.00 to 1.08) 0.85 (0.75 to 0.98)
3 (men ≥25.0, women ≥15.0) 1.46 (1.16 to 1.83) 1.25 (1.02 to 1.52) 1.01 (0.74 to 1.29)
Tertiles of dietary retinol intake level (μg/day)
1 (<503.5) 1.23 (1.10 to 1.37) 1.00 0.73 (0.62 to 0.86)
2 (503.5 to <998.8) 1.20 (1.08 to 1.33) 1.01 (0.96 to 1.06) 0.78 (0.67 to 0.90)
3 (≥998.8) 1.12 (0.90 to 1.34) 1.04 (0.87 to 1.22) 0.94 (0.71 to 1.22)
Data are incidence rate ratio (95% confidence interval) derived from the multivariate adjusted models described
in the text based on a dose-response analysis with pre-defined categories of circulating 25-(OH)D and sex
specific categories of alcohol, and tertiles of retinol intake. Alcohol P value for interaction=0.283. Dietary retinol
P value for interaction=0.030. For the analyses involving retinol, the total number of colorectal cancer case-
control sets is 1220 due to missing nutrient data from Greece.
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